Directorate Change

RNS Number : 2118E

e-Therapeutics plc

07 April 2014

 

e-Therapeutics announces directorate change

Oxford and Newcastle, UK, 7^th April 2014 - e-Therapeutics plc (AIM:ETX) announces that Dr Daniel Elger has resigned as Chief Financial Officer and a Director of e-Therapeutics plc with immediate effect. The Board thanks Dr Elger for his notable contributions to the Company and wishes him the best of luck with future ventures.

In the interim, e-Therapeutics' finances will be managed by Mr Paul Stockdale, who has been the Company's Financial Controller since January 2012. Paul is a Chartered Accountant, and was a Senior Manager at Deloitte before roles in finance and operations management in the charitable and automotive sectors.  He took First Class Honours in Natural Sciences at Cambridge. An announcement concerning succession will be made at the appropriate time.

Contacts:

e-Therapeutics plc

Malcolm Young

Tel: [phone]

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Fred Walsh / Duncan Monteith

Tel: [phone]

www.panmure.com

Instinctif Partners

Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill

Tel: [phone]

Email: [e-mail]

CommStrat Group (US)

Ted Agne

Tel: [phone]

Email: [e-mail]

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system.                    e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.

 

END

 

 

BOABGGDSUSGBGSR